Background
==========

Bladder cancer (BC) is a common malignant urologic cancer. There are 2 major subsets of BC: non-muscle-invasive and muscle-invasive BC. BC is the fifth most common malignancy in the United States, with an estimated 76 960 new cases and 16 390 deaths in 2016 \[[@b1-medscimonit-24-3024]\]. Chronic infection, smoking, and occupation are the main contributory factors of BC \[[@b2-medscimonit-24-3024]\]. Aberrant DNA methylation, an epigenetic change, is believed to be associated with carcinogenesis \[[@b3-medscimonit-24-3024]--[@b5-medscimonit-24-3024]\]. The functions of key genes, including tumor suppressor genes and cell transformation genes, can be affected by changes in methylation, explaining how aberrant DNA methylation is involved in various processes of cancer development \[[@b3-medscimonit-24-3024]\]. Aberrant DNA methylation has also been found in BC. Unlike genetic alterations, DNA methylation is reversible. Therefore, regulation of DNA methylation may represent a new strategy for cancer treatment \[[@b6-medscimonit-24-3024]--[@b8-medscimonit-24-3024]\]. Although some clinical results exist, such as anemia being a prognostic factor of BC \[[@b9-medscimonit-24-3024]\], molecular and genetic biomarkers are considered as promising diagnostic options \[[@b10-medscimonit-24-3024]\]. A few studies on have shown altered DNA methylation in cancer, but the roles of key differentially methylated genes (DMGs) and differentially expressed genes (DEGs) in BC remain unclear.

Recent technological advances in microarray analysis have provided an ideal and reliable method to identify important genetic or epigenetic modifications in cancer development. Thus, there have been many studies on DEGs in BC identified by gene expression profiling using microarrays \[[@b11-medscimonit-24-3024],[@b12-medscimonit-24-3024]\]. Because of limited numbers of samples, individual studies are often not sufficient to demonstrate the underlying mechanism in caner progression. At present, we can obtain more reliable and accurate results by advanced bioinformatics analysis. To obtain novel abnormal methylated/expressed genes and key signaling pathways in BC, we extracted and analyzed information from both microarray-based gene expression and methylation profiling conducted in BC.

Material and Methods
====================

Microarray data
---------------

We extracted gene expression (GSE3167 and GSE65635) and methylation (GSE37816 and GSE33510) profiling data from the Gene Expression Omnibus (GEO) database at the National Center for Biotechnology Information.

The BC-associated dataset GSE3167 submitted by Lars Dyrskjot based on the GPL96 platform (Affymetrix Human Genome U133A Array) was obtained from the GEO database and includes 51 BC samples and 9 normal samples. The BC-associated dataset GSE65635 submitted by Maria Vladimirovna Suntsova based on the GPL14951 platform (Illumina HumanHT-12 WG-DASL V4.0 R2 Expression BeadChip) was obtained from the GEO database and includes 8 BC samples and 4 normal samples. Regarding microarray-based gene methylation profiling, GSE37816 includes 18 BC samples and 6 normal samples, while GSE33510 includes 149 BC samples and 7 normal samples. Both of these methylation microarray analyses used the GPL8490 platform (Illumina HumanMethylation27 BeadChip).

Data processing
---------------

GEO provides users with a useful tool called GEO2R that can be used to analyze microarray data. We used GEO2R to identify DEGs and statistical software R (version 3.3.2, *<http://www.r-project.org/>*) with the minfi R package to identify DMGs. We set P\<0.05 and \|t\| \>2 as the thresholds to identify DEGs and DMGs. First, we identified up- and downregulated genes from the 2 gene expression profiling datasets (GSE3167 and GSE65635). Second, we identified hypo- and hypermethylated genes from GSE37816 and GSE33510. Finally, we identified hypomethylated/upregulated genes via overlapping the hypomethylated and overexpression gene lists and identified hypermethylated/downregulated genes via overlapping the hypermethylated and low-expression gene lists. Statistical software R and the pheatmap R package were used for bidirectional hierarchical clustering.

Functional and pathway enrichment analysis
------------------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID, *<https://david.ncifcrf.gov/>*) provides a set of data-mining tools and thus was used to perform Gene Ontology (GO) term enrichment analysis. GO term enrichment analysis includes biological process, cellular component, and molecular function. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using KOBAS 3.0. P\<0.05 was set as the screening criterion.

Protein--protein interaction (PPI) network construction and module analysis
---------------------------------------------------------------------------

PPI analysis is used to search core genes and gene modules related to carcinogenesis. In this study, PPI network analysis of the hypomethylated/upregulated genes and hypermethylated/downregulated genes were performed using the Search Tool for the Retrieval of Interacting Genes (STRING) database. The interaction score was set at 0.4. Subsequently, modules within the PPI network were screened by Molecular Complex Detection (MCODE) in Cytoscape software. An MCODE score \>3 and number of nodes ≥3 were set as the screening criteria.

Validation of core genes in The Cancer Genome Atlas (TCGA) database
-------------------------------------------------------------------

The TCGA database, which contains a tremendous amount of data on various types of cancers, was used to confirm our results. Most of the core genes selected by PPI analysis were verified in TCGA database.

Results
=======

Identification of DEGs and DMGs in BC
-------------------------------------

After obtaining DEGs and DMGs, 955 overlapping upregulated genes (3526 in GSE3167 and 2731 in GSE65635) and 873 overlapping low-expression genes (5603 in GSE3167 and 2820 in GSE65635) were found from the gene expression microarray analysis. There were 1131 overlapping hypermethylated genes (3881 in GSE37816 and 1691 in GSE33510) and 1767 overlapping hypomethylated genes (3634 in GSE37816 and 2216 in GSE33510) identified by the gene methylation microarray analysis. Further analysis of overlapping genes revealed 71 hypomethylated/upregulated genes and 89 hypermethylated/downregulated genes ([Figure 1A, 1B](#f1-medscimonit-24-3024){ref-type="fig"}; [Supplementary Tables 1](#s1-medscimonit-24-3024){ref-type="supplementary-material"}, [2](#s2-medscimonit-24-3024){ref-type="supplementary-material"}). Visualization of part of aberrantly expressed genes (GSE65635) was illustrated by heat map ([Figure 2](#f2-medscimonit-24-3024){ref-type="fig"}).

GO term analysis
----------------

GO enrichment analysis results are presented in [Table 1](#t1-medscimonit-24-3024){ref-type="table"}. Regarding the biological processes (BP), the hypomethylated/upregulated genes were significantly enriched in cell--cell adhesion, positive regulation of cell growth, and blood vessel development. In the molecular function (MF), the hypomethylated/high-expression genes were enriched in response to poly (A) RNA binding, KDEL sequence binding, and cadherin binding involved in cell--cell adhesion. In the cellular component (CC), the analysis revealed that enrichment mainly occurred at endoplasmic reticulum membrane and cytosol.

The biological processes enriched by the hypermethylated/low-expression genes included positive regulation of cell proliferation, cell adhesion, and signal transduction, and the molecular function included scaffold protein binding, transcription factor activity, and sequence-specific DNA binding. In the cellular component, the hypermethylated/low-expression genes were enriched in integral component of plasma membrane and proteinaceous extracellular matrix.

KEGG pathway analysis
---------------------

According to KEGG analysis ([Table 2](#t2-medscimonit-24-3024){ref-type="table"}), the hypomethylated/high-expression genes were significantly enriched in the fructose and mannose metabolism, p53 signaling, and metabolic pathways. Hypermethylated/low-expression genes were enriched in calcium signaling, insulin secretion, cAMP signaling pathway, and focal adhesion pathways.

PPI network analysis
--------------------

PPI network analysis was performed by STRING database. The PPI network of hypomethylated/upregulated genes is shown in [Figure 3A](#f3-medscimonit-24-3024){ref-type="fig"}. We screened the data and found 3 modules via MCODE in Cytoscape software ([Figure 3C](#f3-medscimonit-24-3024){ref-type="fig"}). KOBAS 3.0 was used for module analysis and demonstrated functions related to *Vibrio cholerae* infection in Module 1, protein export in Module 2, and proteoglycans in cancer Module 3 ([Table 3](#t3-medscimonit-24-3024){ref-type="table"}). The top core genes were chosen: CDH1, DDOST, CASP8, DHX15, and PTPRF ([Figure 3B](#f3-medscimonit-24-3024){ref-type="fig"}). The PPI network of hypermethylated/downregulated genes was constructed ([Figure 4A](#f4-medscimonit-24-3024){ref-type="fig"}) and 2 key modules were found ([Figure 4C](#f4-medscimonit-24-3024){ref-type="fig"}). Module 1 demonstrated functions of GABAergic synapse and Module 2 functions of vascular smooth muscle contraction ([Table 3](#t3-medscimonit-24-3024){ref-type="table"}). The top core genes were revealed: GNG4, ADCY9, NPY, ADRA2B, and PENK ([Figure 4B](#f4-medscimonit-24-3024){ref-type="fig"}).

Validate the identified genes in TCGA database
----------------------------------------------

To confirm our results, the identified core genes were validated in the TCGA database and results are shown in [Table 4](#t4-medscimonit-24-3024){ref-type="table"}. In TCGA, the methylation and expression status of the core genes were also significantly altered in BC samples. These findings suggest that our results were reliable.

Discussion
==========

Aberrant methylation is an important molecular mechanism in BC initiation and development. In the present study, 71 hypomethylated/upregulated genes and 89 hypermethylated/downregulated genes were identified by a variety of bioinformatics analysis. These genes enriched certain pathways and affected by abnormal methylation. Knowledge of the aberrantly methylated/expressed key genes in BC would provide novel insights into its diagnosis, treatment, and prognosis.

In the GO analysis, we found hypomethylated/upregulated genes were significantly enriched in biological processes including cell--cell adhesion, positive regulation of cell growth, and blood vessel development. Regarding molecular function, enrichment of poly (A) RNA binding, KDEL sequence binding, and cadherin binding involved in cell--cell adhesion was found. Cell adhesion is an important factor in cancer dissemination and development of multiple types of cancers, including BC \[[@b13-medscimonit-24-3024]--[@b16-medscimonit-24-3024]\]. Cell growth and blood vessel growth are indispensable for the development of BC. RNA binding-related proteins, such as IGF2BP3 and MSI2, were shown to contribute to cancer cell malignancy and cancer progression \[[@b17-medscimonit-24-3024],[@b18-medscimonit-24-3024]\]. The regulation of hypomethylation for poly (A) RNA binding genes might be associated with the occurrence of BC. KEGG pathway analysis demonstrated that the hypomethylated/upregulated genes significantly enriched in pathways included fructose and mannose metabolism, p53 signaling, and metabolic pathways. Acute myeloid leukemia cells can efficiently utilize fructose, and this promotes the malignant progression of leukemia \[[@b19-medscimonit-24-3024]\]. D-Mannose was suggested as a novel biomarker for early detection of colorectal cancer \[[@b20-medscimonit-24-3024]\]. The p53 signaling pathway has been shown to play an important role in BC \[[@b21-medscimonit-24-3024],[@b22-medscimonit-24-3024]\]. Aberrant metabolism of BC is correlated with bladder tumorigenesis \[[@b23-medscimonit-24-3024]\]. In brief, the dysregulation of fructose and mannose metabolism, p53 signaling, and metabolic pathways might affect BC progression from multiple aspects.

For the hypomethylated/upregulated genes, PPI network analysis was performed. The top 5 core genes were: CDH1, DDOST, CASP8, DHX15, and PTPRF. The CDH1 protein is a subunit of the APC/C complex, which is related to the regulation of cell division. The inactivation of CDH1 *in vivo* results in tumor cell death \[[@b24-medscimonit-24-3024]\]. Maruyama et al. \[[@b25-medscimonit-24-3024]\] first reported that the methylation status of CDH1 was significantly correlated with poor survival in BC. Some drugs induce apoptosis in BC by regulating CASP8 \[[@b26-medscimonit-24-3024],[@b27-medscimonit-24-3024]\]. DHX15 plays multiple roles in tumor progression. In prostate cancer, DHX15 enhances transcriptional activity of the androgen receptor and promotes prostate cancer progression \[[@b28-medscimonit-24-3024]\]. Additionally, DHX15 suppresses tumor proliferation by downregulating the expression of NF-κB in glioma \[[@b29-medscimonit-24-3024]\]. PTPRF is considered a potential biomarker candidate for prostate cancer and non-small cell lung cancer \[[@b30-medscimonit-24-3024],[@b31-medscimonit-24-3024]\]. These results suggest that these core genes play an important role in BC development. Thus, the functions and methylation status of these top core genes in BC warrant additional research.

In the PPI network, module analysis of hypomethylated/high-expression genes suggested that *Vibrio cholerae* infection, protein export, and proteoglycans in cancer are related to BC development. Various proteoglycans, which are key molecular effectors located at the cell surface, perform multiple functions in tumor cell growth, the tumor microenvironment, metastasis, and angiogenesis \[[@b32-medscimonit-24-3024]\]. In addition, important alterations of small leucine-rich proteoglycans in BC have been reported \[[@b33-medscimonit-24-3024]\]. In our study, PTK6, ERBB3, and MAPK13 were correlated with function of proteoglycans in cancers ([Table 3](#t3-medscimonit-24-3024){ref-type="table"}). PTK6 has been demonstrated to be a potential predictive protein in bladder cancer patients \[[@b34-medscimonit-24-3024]\]. ERBB3 was reported to be involved in treatment resistance \[[@b35-medscimonit-24-3024]\]. In high-grade serous ovarian cancer, MAPK13 can serve as a potential predictive protein \[[@b36-medscimonit-24-3024]\]. These results all suggest that PTK6, ERBB3, and MAPK13 genes can serve as potential biomarkers in BC.

In the GO analysis, we found that the hypermethylated/low-expression genes enriched in BP included positive regulation of cell proliferation, cell adhesion, and signal transduction. Cancer is normally considered a genetic disease. Aberrant expression of genes related to positive regulation of cell proliferation, cell adhesion, and signal transduction can affect tumor development and metastasis. Our findings suggest that these hypermethylated/low-expression genes represent promising targets for BC treatment or diagnosis. Regarding molecular functions, hypermethylated/low-expression genes were enriched in scaffold protein binding, transcription factor activity, and sequence-specific DNA binding. Scaffold proteins are an important regulatory factor in many key signaling pathways \[[@b37-medscimonit-24-3024],[@b38-medscimonit-24-3024]\]. There are various scaffold proteins exerting different functions in carcinogenesis. Grp1-associated scaffold protein promotes the function of p53 tumor suppressor genes and inhibits cancer development \[[@b39-medscimonit-24-3024]\]. In our study, we found that many hypermethylated/low-expression genes were enriched in scaffold protein binding. Additional research is needed to determine the function of these hypermethylated/low-expression genes enriched in scaffold protein binding. KEGG analysis revealed enrichment of the genes in the calcium signaling pathway, insulin secretion, cAMP signaling pathway, and focal adhesion, many of which are associated with BC. Calcium signaling is associated with carcinoma *in situ* in the bladder \[[@b40-medscimonit-24-3024]\]. Activation of the cAMP/PKA signaling pathway may inhibit BC cell invasion \[[@b41-medscimonit-24-3024]\]. Focal adhesion kinase (FAK) is a non-receptor protein-tyrosine kinase that is triggered by some growth factors and integrin. Some findings suggest that FAK is involved in oncogenic signaling of invasion and migration in BC \[[@b42-medscimonit-24-3024]\]. In addition, inhibition of FAK induces apoptosis in bladder cancer cells. FAK may function as an important regulator of extracellular signaling-mediated apoptosis in bladder cancer and could be used as a novel therapeutic target in the treatment of BC \[[@b43-medscimonit-24-3024]\]. Our results suggest that these signaling pathways are candidate research targets in BC.

We performed PPI network analysis on hypermethylated/downregulated genes. The top 5 core genes were: GNG4, ADCY9, NPY, ADRA2B, and PENK. ADCY9 is an enzyme that modulates signal transduction, and its expression is correlated with colon cancer TNM staging \[[@b44-medscimonit-24-3024]\]. MiR-181b promotes cell proliferation and reduces apoptosis by downregulating ADCY9 expression in cervical cancer cells \[[@b45-medscimonit-24-3024]\]. GNG4 is a hypermethylated/low-expression gene identified in glioblastoma, and overexpression of GNG4 inhibited the proliferation of glioblastoma cells \[[@b46-medscimonit-24-3024]\]. NPY is a 36-amino acid peptide that acts via G-protein-coupled receptors (Y1--Y6). Peripherally, NPY affects smooth muscle contraction of blood vessels, blood pressure, and atherogenic processes \[[@b47-medscimonit-24-3024]\]. Activation of the Y2 receptor stimulated angiogenesis in various animal models \[[@b48-medscimonit-24-3024]\]. The hypermethylation status of PENK has been validated in BC \[[@b49-medscimonit-24-3024]\]. In multiple types of cancers, PENK serves as a potential diagnostic marker \[[@b50-medscimonit-24-3024],[@b51-medscimonit-24-3024]\]. We found that all top core genes were deeply involve in cancer proliferation or progression, suggesting that these core genes may serve as prognostic biomarkers or therapeutic targets in BC.

According to core modules analysis in the PPI network, hypermethylated/downregulated genes were closely related to GABAergic synapse and vascular smooth muscle contraction. We found that all top 5 core genes with hypermethylated/low-expression were involved in the function of GABAergic synapse. This suggests hypermethylated/low-expression genes related to GABAergic synapse might play an important role in BC development. Until now, the effects of GABAergic synapse in BC and its regulation by aberrant methylation have been unclear.

Several limitations to this investigation should be acknowledged. The clinical application value of those core genes in BCs need further evaluation. Moreover, we only chose related data from the TCGA database as a validated cohort. Our study results need to be validated in more databases.

Conclusions
===========

In conclusion, our research identified some aberrantly expressed genes and pathways potentially regulated by abnormal methylated in BC by integrated analysis of gene expression and methylation microarrays. An analysis of multiple microarray data makes our results more reliable and precise than individual microarray data analysis. This provided a better understanding of the molecular mechanisms underlying the occurrence and progression of BC. Core genes such as CDH1, DDOST, CASP8, DHX15, PTPRF, GNG4, ADCY9, NPY, ADRA2B, and PENK may became new markers in accurate diagnosis and therapy of BC. Further work is needed to determine the role of these identified genes in BC progression.

Supplementary Tables
====================

###### 

The complete list of the 89 hypermethylated/downregulated genes.

  Hypermethylated/low-expression genes                                                                               
  -------------------------------------- -------- --------- -------- --------- --------- -------- --------- -------- ------------
  NPR2                                   HLF      RYR2      ACTA2    LY6H      CCND2     TBX4     ZCCHC14   PEG3     ZNF219
  CHST3                                  RNF122   STXBP6    SEMA3B   PHYHIP    SSBP3     CYP1B1   MYLK      EIF5A2   EMILIN1
  POU6F1                                 RUSC2    NPY       PDLIM4   ITGAM     FLOT1     RAX      LCAT      THBS4    SPARCL1
  DLG4                                   P2RX1    ARMC4     DRD4     AOX1      PLEKHA4   SPON1    NOVA1     LRRC32   ST6GALNAC5
  RARB                                   SYDE1    ADCY9     NNAT     GNG4      PTGFR     VAMP2    HS1BP3    PHF1     RASL12
  KCNMA1                                 ADRA2B   MAP3K14   CUL3     ZNF154    HSF4      KCNA5    STC2      GYPC     BHMT2
  GSTM5                                  VIPR2    ROBO4     CKMT2    HAND2     NCAM2     NEFH     ABCC8     ITGA8    GHSR
  PDE1C                                  HPSE2    HSPB2     BLZF1    ARHGEF4   FEZ1      CX3CL1   GRID2     LTC4S    MAGI2
  HAAO                                   MAP1A    KCNJ6     FAM50B   ACTG2     PENK      CDO1     RELN      JAM2     

###### 

The complete list of the 71 hypomethylated/upregulated genes.

  Hypomethylated/high-expression genes                                                                                  
  -------------------------------------- --------- --------- --------- ---------- ---------- -------- -------- -------- ----------
  HMGN1                                  KRT7      SRP9      VAMP8     ARHGEF18   LYPD3      ENOSF1   TOM1L1   CASP6    TBX3
  SLBP                                   CCDC59    SNRPB2    KRT17     MRPS15     MARCKSL1   SPINT1   KRT20    ERBB3    SERPINB5
  KDELR2                                 EXOSC10   CDH1      KRT8      B4GALT4    MAPK13     CASP8    LYN      ID3      HSD17B4
  TRAM1                                  MKNK2     CCDC47    RALBP1    ARHGDIB    TSTA3      TRAK1    KDELR1   FXYD3    S100A11
  DDOST                                  HDAC1     ISG20L2   SLC25A5   KTN1       SFN        KRT19    CYB5R2   IDH1     BPHL
  CSNK1D                                 AHR       AHCY      SEC61G    FAM3C      SPINT2     TIAM1    PTK6     EPHA1    GNA15
  GRSF1                                  DHX15     TUSC3     GDF15     PTPRF      S100A8     MAP7     DHCR7    SH2D3A   MYO10
  SCAP                                                                                                                  
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![Identification of aberrantly methylated differentially expressed genes in gene expression datasets (GSE3167 and GSE65635) and gene methylation datasets (GSE37816 and GSE33510). (**A**) hypomethylation and upregulated genes. (**B**) hypermethylation and downregulated genes.](medscimonit-24-3024-g001){#f1-medscimonit-24-3024}

![Representative heat map of the top 100 differentially expressed genes in dataset GSE65635 (50 upregulated genes and 50 downregulated genes). Red indicates upregulation and green indicates downregulation.](medscimonit-24-3024-g002){#f2-medscimonit-24-3024}

![PPI network and the top 3 modules of hypomethylation/high-expression genes. (**A**) PPI network. (**B**) Core genes and the number of gene cords. (**C**) Top modules 1--3).](medscimonit-24-3024-g003){#f3-medscimonit-24-3024}

![PPI network and the top 2 modules of hypermethylation/low-expression genes. (**A**) PPI network. (**B**) Core genes and the number of gene cords. (**C**) Top modules 1--2).](medscimonit-24-3024-g004){#f4-medscimonit-24-3024}

###### 

Gene ontology analysis of aberrantly methylated-differentially expressed genes in bladder cancer.

  Category                                  Term                                                                        Count   \%       P value
  ----------------------------------------- --------------------------------------------------------------------------- ------- -------- ---------
  **Hypomethylation and high expression**                                                                                                
  GOTERM_BP_DIRECT                          GO: 0098609\~cell-cell adhesion                                             5       7.0423   0.027
  GOTERM_BP_DIRECT                          GO: 0008284\~positive regulation of cell proliferation                      7       9.8592   0.013
  GOTERM_BP_DIRECT                          GO: 0001568\~blood vessel development                                       3       4.2254   0.011
  GOTERM_BP_DIRECT                          GO: 0009636\~response to toxic substance                                    5       7.0423   0.0004
  GOTERM_BP_DIRECT                          GO: 0051056\~regulation of small GTPase mediated signal transduction        4       5.6338   0.018
  GOTERM_MF_DIRECT                          GO: 0044822\~poly(A) RNA binding                                            10      14.085   0.043
  GOTERM_MF_DIRECT                          GO: 0005046\~KDEL sequence binding                                          2       2.8169   0.008
  GOTERM_MF_DIRECT                          GO: 0098641\~cadherin binding involved in cell-cell adhesion                6       8.4507   0.007
  GOTERM_MF_DIRECT                          GO: 0016853\~isomerase activity                                             3       4.2254   0.003
  GOTERM_MF_DIRECT                          GO: 0005515\~protein binding                                                49      69.014   0.003
  GOTERM_CC_DIRECT                          GO: 0005789\~endoplasmic reticulum membrane                                 11      15.493   0.0016
  GOTERM_CC_DIRECT                          GO: 0043005\~neuron projection                                              6       8.4507   0.0021
  GOTERM_CC_DIRECT                          GO: 0005829\~cytosol                                                        22      30.986   0.011
  GOTERM_CC_DIRECT                          GO: 0005739\~mitochondrion                                                  12      16.901   0.012
  GOTERM_CC_DIRECT                          GO: 0031234\~extrinsic component of cytoplasmic side of plasma membrane     3       4.2254   0.028
  **Hypermethylation and low expression**                                                                                                
  GOTERM_BP_DIRECT                          GO: 0007155\~cell adhesion                                                  10      11.236   0.00035
  GOTERM_BP_DIRECT                          GO: 0008284\~positive regulation of cell proliferation                      8       8.9888   0.007
  GOTERM_BP_DIRECT                          GO: 0007165\~signal transduction                                            12      13.483   0.023
  GOTERM_BP_DIRECT                          GO: 0030198\~extracellular matrix organization                              5       5.618    0.015
  GOTERM_BP_DIRECT                          GO: 0006936\~muscle contraction                                             4       4.4944   0.015
  GOTERM_MF_DIRECT                          GO: 0031697\~beta-1 adrenergic receptor binding                             2       2.2472   0.014
  GOTERM_MF_DIRECT                          GO: 0097110\~scaffold protein binding                                       3       3.3708   0.023
  GOTERM_MF_DIRECT                          GO: 0003700\~transcription factor activity, sequence-specific DNA binding   10      11.236   0.046
  GOTERM_CC_DIRECT                          GO: 0008076\~voltage-gated potassium channel complex                        6       6.7416   0.00005
  GOTERM_CC_DIRECT                          GO: 0005886\~plasma membrane                                                31      34.831   0.005
  GOTERM_CC_DIRECT                          GO: 0005887\~integral component of plasma membrane                          13      14.607   0.031
  GOTERM_CC_DIRECT                          GO: 0005578\~proteinaceous extracellular matrix                             5       5.618    0.036
  GOTERM_CC_DIRECT                          GO: 0008328\~ionotropic glutamate receptor complex                          2       2.2472   0.036

###### 

KEGG pathway analysis of aberrantly methylated-differentially expressed genes in bladder cancer.

  Pathway name                              ID         Gene num   P-value    Genes
  ----------------------------------------- ---------- ---------- ---------- ----------------------------------------------------------
  **Hypomethylation and high expression**                                    
  p53 signaling pathway                     hsa04115   3          0.00029    SFN, ATP1B1, SERPINB5
  Metabolic pathways                        hsa01100   8          0.00171    TSTA3, DHCR7, B4GALT4, AHCY, IDH1, TUSC3, HSD17B4, DDOST
  Fructose and mannose metabolism           hsa00051   2          0.00179    TSTA3, ENOSF1
  **Hypermethylation and low expression**                                    
  Insulin secretion                         hsa04911   5          1.88E-06   ABCC8, ADCY9, KCNMA1, RYR2, VAMP2
  Calcium signaling pathway                 hsa04020   6          4.02E-06   RYR2, P2RX1, ADCY9, PTGFR, PDE1C, MYLK
  cAMP signaling pathway                    hsa04024   5          9.80E-05   ADCY9, GHSR, VIPR2, RYR2, NPY
  Focal adhesion                            hsa04510   5          0.00011    RELN, ITGA8, MYLK, CCND2, THBS4

###### 

Module analysis of the protein--protein interaction network.

  Category                                  Module                                   Function description   FDR   Nodes
  ----------------------------------------- ---------------------------------------- ---------------------- ----- --------------------------------------
  **Hypomethylation and high expression**                                                                         
                                            1\. Vibrio cholerae infection            2.09E-05               3     KDELR2, KDELR1, TUSC3
                                            2\. Protein export                       4.55E-06               3     SEC61G, SRP9, TRAM1
                                            3\. Proteoglycans in cancer              0.00346724             3     PTK6, ERBB3, MAPK13
  **Hypermethylation and low expression**                                                                         
                                            1\. GABAergic synapse                    0.000879043            6     ADRA2B, PENK, ADCY9, DRD4, NPY, GNG4
                                            2\. Vascular smooth muscle contraction   9.22E-07               4     RASL12, ACTA2, MYLK, ACTG2

###### 

Validation of the hub genes in TCGA database.

  Category                                  Hub gene   Methylation status   P value    Expression status   P value
  ----------------------------------------- ---------- -------------------- ---------- ------------------- -------------
  **Hypomethylation and high expression**                                                                  
                                            CDH1       Hypomethylation      9.26E-08   Up-regulated        0.007185916
                                            DDOST                                      Up-regulated        2.45E-11
                                            CASP8      Hypomethylation      9.13E-12   Up-regulated        0.001398258
                                            DHX15                                                          
                                            PTPRF                                      Up-regulated        0.005353039
  **Hypermethylation and low expression**                                                                  
                                            GNG4       Hypermethylation     9.09E-09                       
                                            ADCY9      Hypermethylation     3.21E-06   Down-regulated      8.54E-13
                                            NPY        Hypermethylation     9.48E-11                       
                                            ADRA2B     Hypermethylation     6.15E-11   Down-regulated      0.00036077
                                            PENK       Hypermethylation     1.40E-07   Down-regulated      2.98E-05
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